Actively personalized vaccination trial for newly diagnosed glioblastoma

Mainz, December 20, 2018 – TRON is delighted to announce an article published in Nature.


Working with GAPVAC (Glioma Actively Personalized Vaccine Consortium), TRON participated in developing a highly personalized approach to the treatment of glioblastoma. The consortium publish data on the results of a phase 1 multi-center, multi-national clinical trial, showing favorable safety and immune response results.

Read more about the trial here.

Read more about GAPVAC here.